Celemics, Inc.

Publications

Celemics’ Publications

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen

Vaccine

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen

Baek YJ, Kim W-J, Ko J-H, Lee Y-J, Ahn JY, Kim JH, et al. A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen. Vaccine. 2023;41(10):1694–702.

 

10.1016/j.vaccine.2023.01.063